AzithromycinMD All articles
Antibiotic Stewardship

Beyond the Single Dose: A 2026 Decision Framework for Azithromycin and Doxycycline in Chlamydia Care

AzithromycinMD
Beyond the Single Dose: A 2026 Decision Framework for Azithromycin and Doxycycline in Chlamydia Care

Photo: clinician counseling young adult patient about STI treatment in clinic, via s.yimg.com

For nearly two decades, chlamydia treatment in the United States was effectively a single decision: one gram of azithromycin, observed or delivered, and the visit was over. That era has ended. The shift toward seven days of doxycycline was not a stylistic preference or a cost-saving maneuver; it was driven by accumulating evidence that the single-dose macrolide regimen fails more often, and fails most conspicuously where it matters most. What follows is a practical attempt to place azithromycin accurately in 2026 rather than to retire it prematurely.

The Evidence That Moved the Goalposts

The turning point was a 2014 meta-analysis of randomized trials comparing azithromycin 1 g as a single dose with doxycycline 100 mg twice daily for seven days. Across urogenital infections, doxycycline demonstrated superior microbiologic cure. A subsequent randomized trial in men with urethritis reinforced the finding and, notably, showed a particularly wide gap in rectal infection. Since then, the Centers for Disease Control and Prevention have designated doxycycline as the preferred regimen for chlamydia at nonpregnant adolescents and adults, with azithromycin retained as an alternative rather than a co-equal option.

The magnitude deserves context. Urogenital cure with azithromycin remains high — on the order of 95 percent or better in most series — so this is not a story of an ineffective drug. It is a story of a drug that loses a few more patients per hundred, with the losses concentrated in populations that carry the greatest downstream risk of pelvic inflammatory disease, tubo-ovarian abscess, and ongoing transmission. In stewardship terms, that is enough to change a default.

Site of Infection Changes the Answer

Urogenital infection. Doxycycline 100 mg twice daily for seven days is preferred. Azithromycin 1 g as a single dose remains an acceptable alternative when adherence is genuinely in doubt or when the patient cannot take doxycycline.

Rectal infection. Doxycycline is strongly preferred. The azithromycin failure signal is largest here, and rectal chlamydia is frequently asymptomatic, which means it is often detected only through screening and then treated with whatever the clinic defaults to. The default should be doxycycline.

Oropharyngeal infection. Evidence is thinner for both agents, and neither is reliably excellent. Doxycycline remains the reasonable first choice, with test-of-cure consideration in persistent symptoms.

Pelvic inflammatory disease. This is a separate pathway. Outpatient regimens pair a single intramuscular dose of ceftriaxone with doxycycline plus metronidazole for fourteen days, and azithromycin's role in that context is adjunctive at most. Do not extrapolate urogenital chlamydia logic here.

Pregnancy: Azithromycin's Clearest Remaining Indication

In pregnancy, azithromycin 1 g as a single dose remains the recommended regimen. Doxycycline is generally avoided during pregnancy and lactation on the basis of tetracycline-class concerns, even though contemporary evidence suggests the absolute risk from a short course is lower than older warnings imply. Absent a change in guidance, the practical consequence is that azithromycin retains a genuinely important role in obstetric care, and clinicians should not let the general drift toward doxycycline erode it.

Two obligations attach to the pregnancy scenario. First, arrange a test of cure at approximately three to four weeks after treatment, since reinfection and treatment failure both carry obstetric consequences. Second, confirm partner treatment; a cured patient with an untreated partner is a temporary state.

Adherence, Adolescents, and Partner-Delivered Therapy

The single-dose regimen still solves real problems. A seven-day course assumes a patient will return to a pharmacy, remember twice-daily dosing, and complete therapy despite gastrointestinal upset. For patients with unstable housing, shift work, or prior non-completion, directly observed azithromycin may produce a better real-world cure rate than a theoretically superior regimen that goes unfinished.

Expedited partner therapy for chlamydia is endorsed by the CDC and permitted in most states, though legal status varies and should be verified locally. Both azithromycin and doxycycline have been used as partner-delivered regimens; the practical selection often hinges on state law, cost, and whether the partner is pregnant. Adolescents warrant a specific note: short-course doxycycline is no longer considered contraindicated in children of any age for rickettsial and chlamydial indications, so age alone is not a reason to default to azithromycin.

Counseling That Differs Meaningfully Between Regimens

Patients notice the difference in instructions even when they do not notice the pharmacology.

Retesting and the Three-Month Rule

Universal retesting at three months is recommended for all patients treated for chlamydia, regardless of regimen, because reinfection rates are high. A test of cure at three to four weeks is reserved for pregnancy and for situations in which adherence or regimen adequacy is uncertain. Treating physicians should build this into the after-visit summary rather than relying on patient recall.

A Practical Framework for 2026

Ask three questions in sequence. Is the patient pregnant? If yes, azithromycin 1 g as a single dose with a test of cure. Is the infection rectal or is adherence reliable? If rectal, doxycycline. If adherence is genuinely unreliable, azithromycin with documented rationale. Is there urethritis or cervicitis with a negative chlamydia result? Then test for Mycoplasma genitalium, where azithromycin resistance is now common enough that empiric single-dose therapy is no longer defensible.

The headline for clinicians is not that one drug won. It is that chlamydia management has become specific — site-specific, pregnancy-specific, adherence-specific — and the formulary choice carries enough consequence to justify a moment of deliberation before the prescription prints.

All Articles

Related Articles

The Cabinet Pharmacy: Confronting Leftover Azithromycin and the Rise of Patient Self-Treatment

The Cabinet Pharmacy: Confronting Leftover Azithromycin and the Rise of Patient Self-Treatment

Priced at Pennies, Prescribed by the Millions: How Generic Azithromycin Reshaped the American Prescription Landscape

Priced at Pennies, Prescribed by the Millions: How Generic Azithromycin Reshaped the American Prescription Landscape

Convenience at What Cost? Guardrails for Azithromycin Prescribing in the Telehealth Era

Convenience at What Cost? Guardrails for Azithromycin Prescribing in the Telehealth Era